Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
HMS advances the healthcare system by helping healthcare organizations reduce cost...
HMS advances the healthcare system by helping h...
Health Journal is a leader and influencer in health publishing in Virginia, USA an...
Health Journal is a leader and influencer in he...
Founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and ...
Founded in 1996 as a spinoff from the Harvard-M...
Eidos is a clinical stage biopharmaceutical company focused on addressing the larg...
Eidos is a clinical stage biopharmaceutical com...
We are a biotechnology company focused on delivering transformational therapies fo...
We are a biotechnology company focused on deliv...
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the develo...
Puma Biotechnology, Inc. is a biopharmaceutical...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Join the National Investor Network and get the latest information with your interests in mind.